PT  - JOURNAL ARTICLE
AU  - Alexander, Lori
ED  - Scirica, Benjamin M.
TI  - TRA 2°P-TIMI 50 Results
DP  - 2012 Nov 01
TA  - MD Conference Express
PG  - 23--24
VI  - 12
IP  - 13
4099  - http://mdc.sagepub.com/content/12/13/23.short
4100  - http://mdc.sagepub.com/content/12/13/23.full
AB  - For patients with a history of myocardial infarction (MI) who are stable, the addition of vorapaxar to the standard of care reduced the long-term risk of cardiovascular death or ischemic events and increased the risk of moderate or severe bleeding. The efficacy and safety of the drug were evaluated for secondary prevention in a broad group of patients with prior MI, prior stroke, or peripheral artery disease in the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 [TRA 2°P-TIMI 50] trial.